Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prevymis

PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16

HOS-139828 · Präparat HOS-098408

Anti-arrhythmic medicinal products amiodarone Interaction not studied. Letermovir may increase the plasma Expected: concentrations of amiodarone. ↑ amiodarone Frequent monitoring for adverse reactions (primarily CYP3A inhibition related to amiodarone is recommended and CYP2C8 inhibition or during co-administration. Monitoring of induction) amiodarone concentrations should be performed regularly when amiodarone is co-administered with letermovir#. quinidine Interaction not studied. Letermovir may increase the plasma Expected: concentrations of quinidine. ↑ quinidine Close clinical monitoring should be (CYP3A inhibition) exercised during administration of letermovir with quinidine. Refer to the respective prescribing information#. Cardiovascular medicinal products digoxin‡ ↔ digoxin No dose adjustment required. (0.5 mg single dose)/ AUC 0.88 (0.80, 0.96) letermovir (240 mg Cmax 0.75 (0.63, 0.89) twice daily) (P-gp induction) Proton pump inhibitors omeprazole Interaction not studied. Letermovir may decrease the plasma Expected: concentrations of CYP2C19 substrates. ↓omeprazole Clinical monitoring and dose adjustment (induction of CYP2C19) may be needed.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quinidine (HOS-085593) digoxin (HOS-086172) amiodarone (HOS-085596) omeprazole (HOS-085912)